-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS: Johnson & Johnson's acquisition of Ollin proves that Cinda Biotech (01801) ophthalmology R&D was approved

Zhitongcaijing·11/17/2026 07:17:05
Listen to the news

The Zhitong Finance App learned that UBS released a research report saying that Cinda Biotech's (01801) partner Ollin will be acquired by Johnson & Johnson, and the core three-phase asset IBI/OLN324 (Ang2/VEGF) will be incorporated into the Johnson & Johnson pipeline. The bank has a positive view on this; maintaining Cinda Biotech's “buy” rating and target price of HK$135.3.

The bank stated that the deal confirmed Cinda Biotech's strength in ophthalmology research and development, including an advance payment of US$2.2 billion and a milestone payment of up to US$1,125 million. IBI/OLN324 in WAMD/DME phase 1b clinical data were positive compared to faricimab. Kuroishi will pay Johnson & Johnson USD 750 million to fully fund the OLN324 Phase III clinical trial in exchange for certain milestones and unit royalties.